Study Evaluating the Safety and Tolerability of Single Ascending Dose (SAD) SLV-351 in Healthy Subjects

Ascending Single Dose Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SLV-351 Administered Orally to Healthy Subjects

Status

Terminated

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00581191

Enrollment

Registered

2007-12-27

Start date

2008-01-31

Completion date

2008-03-31

Last updated

2009-08-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Keywords

SAD, Healthy

Brief summary

Safety and tolerability of single oral doses in healthy subjects.

Interventions

DRUGSLV-351

SLV-351 capsules taken once

Study design

Allocation

RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 50 Years

Healthy volunteers

Yes

Inclusion criteria

* Men, aged 18-50 years. * Women of nonchildbearing potential, aged 18-50 years.

Design outcomes

Primary

Measure	Time frame
Safet and tolerability	35 days

Secondary

Measure	Time frame
PK and PD	35 days

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026